MTAP and prostate carcinoma: The castration-resistant prostate cancer cells used in this study, C4-2 and DU145, are MTAP-proficient [42], thus the differential toxicity of 6-TG in cancer versus normal prostate cells cannot be ascribed to a deficiency of MTAP in prostate cancer cells.